1. Evaluation of the Tolerability of Gemcitabine and Cisplatin Combination Chemotherapy with a Small Quantity of Replacement Fluid for Biliary Tract Cancer
- Author
-
Kaoru Murakami, Atsuko Minemura, Tadanori Sasaki, Takenori Ichimura, Masahiro Usuda, Daisuke Ichikura, Shuichi Nawata, and Wataru Kawashima
- Subjects
Adult ,Male ,medicine.medical_specialty ,Side effect ,Urology ,Pharmaceutical Science ,Deoxycytidine ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Medicine ,Adverse effect ,Aged ,Retrospective Studies ,Aged, 80 and over ,Pharmacology ,Cisplatin ,business.industry ,Combination chemotherapy ,Acute Kidney Injury ,Middle Aged ,Gemcitabine ,Confidence interval ,Discontinuation ,Biliary Tract Neoplasms ,Tolerability ,Fluid Therapy ,Female ,business ,medicine.drug - Abstract
Cisplatin therapy induces kidney injury as a side effect. Thus, replacement fluid must be administered to prevent kidney injury. In our hospital, we use a Gemcitabine and Cisplatin combination chemotherapy (GC) at a total volume of approximately 500 mL for biliary tract cancer. We investigated the safety of GC with a small amount of replacement fluid. As a result, no serious adverse events and renal injury occurred that required discontinuation of treatment. The median overall survival time was 260 d (95% confidence interval, 154-367 d). This study suggests that GC with a small amount of replacement fluid could be performed tolerability. But we need to be careful about choosing patients such as patients who can drink 1 L orally and patients who can be treated as outpatients.
- Published
- 2020
- Full Text
- View/download PDF